NR 567 Exam 1 V3 | NR 567 Advanced
Pharmacology for the AGACNP | Actual
Q&A with Rationale (NR567 Exam 1) |
Chamberlain College of Nursing
1. When calculating the volume of distribution (Vd) for a specific drug, the AGACNP
understands that a drug with a very high Vd typically indicates which of the following?
A. The drug is primarily confined to the intravascular space.
B. The drug has distributed extensively into the body tissues.
C. The drug is highly water-soluble and ionized at physiological pH.
D. The drug has a very short half-life due to rapid renal excretion.
Correct Answer: B
The volume of distribution is a theoretical value that compares the amount of drug in the
body to the concentration measured in the plasma. A high Vd suggests that the drug is
lipophilic or highly bound to tissue proteins, causing it to leave the vascular compartment.
This information is clinically significant when determining whether a loading dose is
necessary to achieve therapeutic levels quickly.
2. A patient is prescribed a medication that is a known potent inhibitor of the CYP3A4 enzyme
system. If this patient is also taking a second drug metabolized by the same system, what is
the most likely pharmacological outcome?
A. The second drug will be excreted more rapidly by the kidneys.
,B. The plasma levels of the second drug will increase, potentially reaching toxic levels.
C. The second drug will have a decreased half-life.
D. The second drug will become less bioavailable due to increased first-pass metabolism.
Correct Answer: B
CYP450 inhibitors slow down the metabolic breakdown of substrate drugs that share the
same pathway. When metabolism is inhibited, the clearance of the substrate drug decreases,
leading to accumulation in the systemic circulation. Practitioners must closely monitor for
drug toxicity and consider dose reductions when adding an inhibitor to a stable drug regimen.
3. The AGACNP is reviewing the concept of ‘Steady State’ for a patient starting a new anti-
arrhythmic medication. How many half-lives are generally required for a drug to reach a
steady-state plasma concentration?
A. 1 to 2 half-lives
B. 4 to 5 half-lives
C. 7 to 10 half-lives
D. Steady state is reached immediately after the first dose.
Correct Answer: B
Steady state is achieved when the rate of drug administration equals the rate of drug
elimination. It typically takes approximately four to five half-lives for the plasma
, concentration of a drug to stabilize during continuous dosing. Understanding this timeline is
essential for determining when to measure therapeutic drug levels to ensure accuracy.
4. Which of the following factors are known to significantly influence the rate and extent of
drug absorption from the gastrointestinal tract? (Select All That Apply)
A. Gastric emptying time and intestinal motility
B. Surface area available for absorption
C. Blood flow to the gastrointestinal mucosa
D. The lipid solubility and ionization state of the drug
E. The presence of food or other medications in the stomach
F. The patient’s current height and skeletal muscle mass
Correct Answer: A, B, C, D, E
Absorption is the process of a drug moving from the site of administration into the
bloodstream. Factors such as pH, surface area, and blood flow determine how efficiently a
drug crosses biological membranes. Clinicians must account for these variables, especially in
patients with malabsorption syndromes or gastric bypass surgery, to ensure therapeutic
efficacy.
5. A patient with chronic kidney disease (CKD) is prescribed a drug that is primarily eliminated
via the renal route. What adjustment should the AGACNP anticipate?
A. No adjustments are necessary if the liver function is normal.
Pharmacology for the AGACNP | Actual
Q&A with Rationale (NR567 Exam 1) |
Chamberlain College of Nursing
1. When calculating the volume of distribution (Vd) for a specific drug, the AGACNP
understands that a drug with a very high Vd typically indicates which of the following?
A. The drug is primarily confined to the intravascular space.
B. The drug has distributed extensively into the body tissues.
C. The drug is highly water-soluble and ionized at physiological pH.
D. The drug has a very short half-life due to rapid renal excretion.
Correct Answer: B
The volume of distribution is a theoretical value that compares the amount of drug in the
body to the concentration measured in the plasma. A high Vd suggests that the drug is
lipophilic or highly bound to tissue proteins, causing it to leave the vascular compartment.
This information is clinically significant when determining whether a loading dose is
necessary to achieve therapeutic levels quickly.
2. A patient is prescribed a medication that is a known potent inhibitor of the CYP3A4 enzyme
system. If this patient is also taking a second drug metabolized by the same system, what is
the most likely pharmacological outcome?
A. The second drug will be excreted more rapidly by the kidneys.
,B. The plasma levels of the second drug will increase, potentially reaching toxic levels.
C. The second drug will have a decreased half-life.
D. The second drug will become less bioavailable due to increased first-pass metabolism.
Correct Answer: B
CYP450 inhibitors slow down the metabolic breakdown of substrate drugs that share the
same pathway. When metabolism is inhibited, the clearance of the substrate drug decreases,
leading to accumulation in the systemic circulation. Practitioners must closely monitor for
drug toxicity and consider dose reductions when adding an inhibitor to a stable drug regimen.
3. The AGACNP is reviewing the concept of ‘Steady State’ for a patient starting a new anti-
arrhythmic medication. How many half-lives are generally required for a drug to reach a
steady-state plasma concentration?
A. 1 to 2 half-lives
B. 4 to 5 half-lives
C. 7 to 10 half-lives
D. Steady state is reached immediately after the first dose.
Correct Answer: B
Steady state is achieved when the rate of drug administration equals the rate of drug
elimination. It typically takes approximately four to five half-lives for the plasma
, concentration of a drug to stabilize during continuous dosing. Understanding this timeline is
essential for determining when to measure therapeutic drug levels to ensure accuracy.
4. Which of the following factors are known to significantly influence the rate and extent of
drug absorption from the gastrointestinal tract? (Select All That Apply)
A. Gastric emptying time and intestinal motility
B. Surface area available for absorption
C. Blood flow to the gastrointestinal mucosa
D. The lipid solubility and ionization state of the drug
E. The presence of food or other medications in the stomach
F. The patient’s current height and skeletal muscle mass
Correct Answer: A, B, C, D, E
Absorption is the process of a drug moving from the site of administration into the
bloodstream. Factors such as pH, surface area, and blood flow determine how efficiently a
drug crosses biological membranes. Clinicians must account for these variables, especially in
patients with malabsorption syndromes or gastric bypass surgery, to ensure therapeutic
efficacy.
5. A patient with chronic kidney disease (CKD) is prescribed a drug that is primarily eliminated
via the renal route. What adjustment should the AGACNP anticipate?
A. No adjustments are necessary if the liver function is normal.
